These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35656636)

  • 41. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.
    Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B
    J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.
    Moreno L; Teira P; Croop JM; Gerber NU; André N; Aerts I; Gros Subias L; De Wilde B; Bautista F; Turpin B; Kunduri S; Hamidi A; Lawrence T; Streby KA
    Front Pediatr; 2023; 11():1183295. PubMed ID: 37292376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
    Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
    JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.
    Masoud SJ; Hu JB; Beasley GM; Stewart JH; Mosca PJ
    Ann Surg Oncol; 2019 Dec; 26(13):4633-4641. PubMed ID: 31414290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
    Miller DM; Trowbridge RM; Desai A; Drews RE
    J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
    Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retreatment with talimogene laherparepvec for advanced melanoma.
    Hu J; Masoud SJ; Ravichandran S; Beasley GM; Mosca PJ
    Immunotherapy; 2020 Nov; 12(16):1167-1172. PubMed ID: 32840157
    [No Abstract]   [Full Text] [Related]  

  • 50. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.
    Ahamadi M; Kast J; Chen PW; Huang X; Dutta S; Upreti VV
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):250-260. PubMed ID: 36564918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
    Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
    Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma.
    Mulder EEAP; Damman J; Verver D; van der Veldt AAM; Tas S; Khemai-Mehraban T; Heezen KC; Wouters RA; Verhoef C; Verjans GMGM; Langerak AW; Grünhagen DJ; Mooyaart AL
    Melanoma Res; 2022 Aug; 32(4):249-259. PubMed ID: 35446267
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
    Queen D; Samie FH; Zeitouni NC
    Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
    [No Abstract]   [Full Text] [Related]  

  • 54. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
    Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
    Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
    Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
    J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
    Chitnis SD; Seim NB; Kendra K
    J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
    Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
    Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database.
    Louie KS; Banks V; Scholz F; Richter H; Öhrling K; Mohr P; Haferkamp S
    Future Oncol; 2020 Mar; 16(8):317-328. PubMed ID: 32050787
    [No Abstract]   [Full Text] [Related]  

  • 60. The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis.
    Wang C; Lu N; Yan L; Li Y
    Virol J; 2023 Nov; 20(1):252. PubMed ID: 37919738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.